Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory...
Arcus executes on strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), including three new clinical trial collaborations that...
Barchart Research What to Expect from RCUS Earnings RCUS Generated August 4, 2026 Current Price $28.80 EPS Estimate $$-1.01 Consensus Rating Moderate Buy Average Move 3.84% Will Arcus Biosciences Finally...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory...
This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy...
Data Expected to Be Generated by Mid-2027
Data Expected to Be Generated by Mid-2027
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory...
This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology ...